Vanguard Group Inc. Trims Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Vanguard Group Inc. cut its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 2.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,012,793 shares of the life sciences company’s stock after selling 147,061 shares during the period. Vanguard Group Inc. owned approximately 8.97% of Integra LifeSciences worth $305,407,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IART. Signaturefd LLC raised its stake in shares of Integra LifeSciences by 248.5% during the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after buying an additional 415 shares in the last quarter. Hexagon Capital Partners LLC raised its stake in shares of Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after buying an additional 370 shares in the last quarter. Gladius Capital Management LP purchased a new position in shares of Integra LifeSciences during the 3rd quarter worth approximately $47,000. Mitsubishi UFJ Asset Management UK Ltd. purchased a new position in shares of Integra LifeSciences during the 4th quarter worth approximately $131,000. Finally, International Assets Investment Management LLC purchased a new position in shares of Integra LifeSciences during the 4th quarter worth approximately $190,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of analyst reports. Bank of America cut their target price on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a research note on Tuesday, May 7th. Oppenheimer cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 7th. JMP Securities lowered their price target on Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating on the stock in a report on Tuesday, May 7th. Citigroup upped their price target on Integra LifeSciences from $24.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, May 22nd. Finally, Truist Financial lowered their price target on Integra LifeSciences from $37.00 to $25.00 and set a “hold” rating on the stock in a report on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $33.88.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $29.14 on Friday. The business’s fifty day moving average price is $28.61 and its two-hundred day moving average price is $35.66. The stock has a market cap of $2.30 billion, a PE ratio of 58.28, a price-to-earnings-growth ratio of 1.04 and a beta of 1.17. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.35 and a current ratio of 4.68. Integra LifeSciences Holdings Co. has a one year low of $22.36 and a one year high of $46.75.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55. The firm had revenue of $368.90 million for the quarter, compared to analysts’ expectations of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. Integra LifeSciences’s quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.74 EPS. On average, analysts forecast that Integra LifeSciences Holdings Co. will post 3.03 EPS for the current fiscal year.

Insider Activity

In other Integra LifeSciences news, Chairman Stuart Essig acquired 52,641 shares of the stock in a transaction dated Thursday, May 23rd. The stock was acquired at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the completion of the transaction, the chairman now directly owns 487,922 shares in the company, valued at $13,900,897.78. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 3.10% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.